StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for HAE yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $56.30 | $57.28 | +1.74% | 0.6M |
| 05-19 | $57.72 | $56.85 | -1.51% | 0.6M |
| 05-20 | $56.63 | $59.56 | +5.17% | 1.0M |
| 05-21 | $58.91 | $61.94 | +5.14% | 1.2M |
| 05-22 | $64.49 | $65.49 | +1.55% | 1.0M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2026 2026-03-28 | Q4 2025 2025-12-27 | Q3 2025 2025-09-27 | Q2 2025 2025-06-28 |
|---|---|---|---|---|
Revenue | $1.33B | $987.68M | $648.71M | $321.39M |
Operating Income | $156.73M | $179.76M | $112.36M | $53.87M |
Net Income | $97.31M | $117.45M | $38.68M | $34.03M |
EPS (Diluted) | $2.05 | $2.46 | $1.51 | $0.70 |
Total Assets | $2.40B | $2.49B | $2.44B | $2.46B |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $245.44M | $363.37M | $296.43M | $292.90M |
Free Cash Flow OCF − CapEx | $260.44M | $207.16M | $119.95M | $13.64M |
Shares Outstanding | 45.25M | 46.83M | 46.75M | 48.16M |